Blog

Using Artificial Intelligence to Optimise Small-Molecule Drug Design

Here at BenevolentAI, we are unlocking the power of scientific data so no disease goes untreated.

We achieve this in a variety of ways, right from initial target identification and validation, through hit discovery and lead optimisation, and finally into the clinic, making us the only end-to-end drug discovery company driven by Artificial Intelligence (AI) in the world.

We power this innovation by using structured and unstructured data sources to learn new insights and relationships at scale that otherwise would not be possible. Here, a key differentiator is how we use AI to extract the knowledge locked in the scientific literature and patents to boost our knowledge graph of entity relationships of genes, targets, molecules, and diseases.

My role at BenevolentAI, as head of the Chemoinformatics team, is to guide the scientific direction and validity in the development of our molecular design platform. The size of drug-like chemistry space is truly vast. As an analogy, if we take six Lego bricks, it is possible to construct them in almost one billion unique configurations. Replacing the bricks for atoms, and scaling the number up from six to the more typical size of a drug-like molecule of 20-30 heavy atoms, the size of the space expands dramatically to truly astronomical proportions. The size of this space makes it technically challenging to exhaustively examine every theoretical molecule, instead we use advanced AI algorithms to effectively sample that space to explore and exploit the most promising candidates to take to synthesis and testing.

Drug discovery itself is an inherently multiobjective optimisation process, with many different parameters needed to be optimised in concert. We score each of the candidate solutions with multiple predictive models using a range of appropriate parameters, including the introduction of synthetic tractability, and even planning synthetic routes.

The platform we have developed at BenevolentAI gives us the power to not only tell our scientists what to make, but also how to make the molecules that are of most relevance to our drug discovery programmes, thereby helping to optimise the whole of our AI-driven drug discovery pipeline.

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022